Building new cancer therapies atom by atom. ABOUT US Nanobiotix is a late-stage clinical biotechnology company that is pioneering the discovery, development, manufacture, and commercialization of physics-based nanotherapeutics. We aim to create products that will transform outcomes for millions of people fighting cancer worldwide. About Us Our lead candidate NBTXR3 is a potential first-in-class radioenhancer […]
NBTXR3 radio-enhancing nanoparticle achieves a more robust antitumor immune response when combined with proton radiotherapy than photon radiotherapy
Nanobiotix Publications and Abstracts Early biological impacts of radiotherapy-activated NBTXR3 nanoparticles Early biological impacts of radiotherapy-activated NBTXR3 nanoparticles
Early biological impacts of radiotherapy-activated NBTXR3 nanoparticles Lire la suite »
ASTRO 2023 65th Annual Meeting of American Society for Radiation Oncology 1st–4th October, 2023San Diego Convention Center, San Diego, CA, USA Nanobiotix will be presenting (oral presentation) the final readout on primary objectives from Study 102 Dose Expansion—the expansion part of a phase I dose escalation and dose expansion study evaluating potential first-in-class radioenhancer NBTXR3
Pour en savoir plus sur nos technologies, nos collaborations, nos essais cliniques ou tout autre sujet, contactez-nous.
